Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Sofosbuvir As a Potential Option for the Treatment of Covid-19 Publisher Pubmed



Nourian A1 ; Khalili H1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmacotherapy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: Acta Biomedica Published:2020


Abstract

Summary. Sofosbuvir may be a potential option in the treatment of COVID-19 based on the similarity between the replication mechanisms of the HCV and the coronavirus. According the limited experimental evidences, it is hypothesized that sofosbuvir might be a potential option to improve care of patients with COVID-19 especially at the start of the disease and before invasion of the virus into the lung parenchymal cells. Efficacy and safety of sofosbuvir in treatment of COVID-19 may be considered in future clinical studies. (www.actabiomedica.it). © Mattioli 1885.
Related Docs
1. Efficacy and Safety of Sofosbuvir/ Ledipasvir in Treatment of Patients With Covid-19; a Randomized Clinical Trial, Acta Biomedica (2020)
2. Sofosbuvir and Daclatasvir Compared With Standard of Care in the Treatment of Patients Admitted to Hospital With Moderate or Severe Coronavirus Infection (Covid-19): A Randomized Controlled Trial, Journal of Antimicrobial Chemotherapy (2020)
3. Evaluation of the Efficacy of Sofosbuvir Plus Daclatasvir in Combination With Ribavirin for Hospitalized Covid-19 Patients With Moderate Disease Compared With Standard Care: A Single-Centre, Randomized Controlled Trial, Journal of Antimicrobial Chemotherapy (2020)
Experts (# of related papers)
View all Related Experts
Hossein Khalili (1)
Sirous Jafari (1)